Anticoagulants & Antiplatelets Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Anticoagulants and Antiplatelet Agents DMPK and Bioanalytical Services

Seven antithrombotic agents, seven analytical identities — none interchangeable. Warfarin is CYP-substrate-only. Dabigatran is P-gp-substrate-only, no CYP. Rivaroxaban and apixaban are CYP+P-gp, apixaban adding BCRP. Ticagrelor is CYP3A4+P-gp substrate AND inhibitor. Clopidogrel is an esterase-activated P-gp prodrug. Aspirin is esterase-only, no transporters. A generic LC-MS/MS method that assumes all seven follow the same clearance route will fail on six of them.

Creative Proteomics provides permutation-aware DMPK workflows spanning CYP-metabolic profiling, P-gp and BCRP transporter disposition, esterase-stabilized prodrug activation monitoring, CYP inhibitor-aware DDI risk assessment, and custom multi-agent panels.

Browse Drug Index Request Custom Method Support

CYP × Transporter × Prodrug PermutationsSeven agents, each with a unique (CYP isoforms × P-gp/BCRP × esterase × prodrug) signature. No two are analytically equivalent.

Clopidogrel: The Esterase ProdrugRequires esterase-stabilized sampling and CYP2C19 activation monitoring. CYP-only or transporter-only misses the prodrug dimension.

Ticagrelor: Substrate + Inhibitor DDI RiskCYP3A4 substrate AND inhibitor. Co-incubation with probe substrates requires inhibitor-aware controls.

Antithrombotic Permutation Risks DMPK Strategy Map

⚡

Permutation ClassificationSeven agents, each with a unique (CYP isoforms × P-gp/BCRP × esterase × prodrug × inhibitor) signature. No two are analytically equivalent.

🧬

CYP-Dependent Metabolism & MetIDWarfarin (CYP2C9/1A2/3A4), rivaroxaban (CYP3A4/2J2), apixaban (CYP3A4), ticagrelor (CYP3A4) require multi-isoform microsome/hepatocyte incubation.

📊

Transporter-Mediated DispositionDabigatran (P-gp), rivaroxaban/apixaban/ticagrelor/clopidogrel (P-gp), apixaban (BCRP) require transporter-substrate classification and disposition analysis.

🔬

Esterase Prodrug & Inhibitor DDI RiskClopidogrel requires esterase-stabilized prodrug activation. Ticagrelor requires inhibitor-compensated DDI profiling. Aspirin requires esterase-only metabolism.

Antithrombotic agent permutation triage.Creative Proteomics maps the complete (CYP × transporter × esterase × prodrug × inhibitor) signature before method development — because a workflow that fits warfarin (CYP-only) has no analytical relevance to dabigatran (P-gp-only, no CYP).

Antithrombotic Drug Index

Find the Antithrombotic Agent Behind the Study

Antithrombotic studies split by a key question: what is the compound’s (CYP × transporter × esterase × prodrug) signature? Use the index to identify which analytical dimensions apply — and which don’t — before method development. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only agents matching all selected values.

7 entries · Page 1 of 4

Analytical Pain Points

What Drives Assay Failure in Antithrombotic Studies?

Antithrombotic agents fail analytically when treated as one class. A CYP incubation works for warfarin and rivaroxaban but sends dabigatran down a metabolic path it doesn’t take. P-gp inhibition controls apply to apixaban but are irrelevant to aspirin. Clopidogrel needs esterase stabilization but rivaroxaban doesn’t.

Seven Agents, Seven Permutation Signatures

Each compound has a unique (CYP × P-gp × BCRP × esterase × prodrug) signature. Warfarin is CYP-only. Dabigatran is P-gp-only. Apixaban is CYP+P-gp+BCRP. Clopidogrel is esterase-prodrug+P-gp. One method cannot serve all seven.

Our responsePermutation-aware workflows that classify each agent by its complete (CYP × transporter × esterase × prodrug) signature before method development begins.

LC-MS/MS Drug Quantification →

Clopidogrel’s Dual-Activation Prodrug Strategy

Clopidogrel is an esterase-activated prodrug, further metabolized by CYP2C19. Without esterase inhibitor in collection and processing, ex vivo activation produces falsely elevated active metabolite levels.

Our responseEsterase-stabilized sampling with simultaneous prodrug-active metabolite quantification and CYP2C19-genotyped incubation.

Simultaneous Parent-Metabolite Panels →

Ticagrelor Inhibits the Enzyme That Metabolizes It

Ticagrelor is a CYP3A4 substrate and a CYP3A4 inhibitor. Co-incubating it with a CYP3A4 probe substrate produces competitive inhibition artifacts — DDI risk from ticagrelor itself, not from the test compound under investigation.

Our responseSequential incubation protocols with separate substrate-depletion and probe-inhibition readouts to disentangle ticagrelor’s own inhibitory effect.

CYP Inhibition Assays →

Apixaban’s Dual-Transporter Disposition: P-gp + BCRP

Apixaban is a substrate of both P-gp and BCRP. P-gp efflux and BCRP transport interact to determine systemic exposure. A P-gp-only analysis misses BCRP contribution; a CYP-only analysis misses both transporters.

Our responseDual P-gp/BCRP transporter-substrate classification with CYP3A4 metabolism profiling and transporter-informed exposure interpretation.

Complex Biological Matrices →

Mixed-Class Panels Require Dimension-Aware Method Design

A panel spanning CYP substrates, P-gp substrates, an esterase prodrug, a BCRP substrate, and an esterase-only compound needs incubation conditions, transporter controls, esterase stabilization, and DDI probe arms designed for permutation heterogeneity.

Our responseCustom multi-agent LC-MS/MS panels with dimension-aware incubation, esterase-stabilized sampling for clopidogrel, and inhibitor-compensated DDI readouts for ticagrelor.

Custom Panels →

Focused Service Paths

Four Practical Routes for Antithrombotic Studies

Antithrombotic workflows should be selected according to the compound’s permutation signature: CYP-metabolic for warfarin, CYP+P-gp for rivaroxaban/apixaban, transporter-only for dabigatran, esterase-prodrug for clopidogrel, inhibitor-aware for ticagrelor, esterase-only for aspirin, or multi-agent panels for mixed-signature designs.

CYP-Metabolic Profiling & MetID

For warfarin, rivaroxaban, and apixaban — CYP-mediated Phase I metabolism in microsome/hepatocyte models.

Multi-CYP incubation (CYP2C9/1A2/3A4/2J2)
Phase I metabolite profiling
DDI-risk-aware design for CYP3A4 substrates

Phase I & II Metabolite Characterization →

Esterase Prodrug Activation & Monitoring

For clopidogrel and aspirin — esterase-stabilized prodrug activation monitoring and parent-drug quantification.

Esterase-stabilized sampling for clopidogrel
CYP2C19-genotyped incubation
Prodrug-active metabolite simultaneous quantification

Simultaneous Parent-Metabolite Panels →

Transporter-Mediated Disposition Studies

For dabigatran (P-gp), rivaroxaban/apixaban/ticagrelor/clopidogrel (P-gp), and apixaban (BCRP) — transporter substrate classification and disposition analysis.

P-gp and BCRP substrate profiling
CYP-P-gp interplay assessment
Transporter-informed exposure interpretation

Transporter Interaction Bioanalysis →

Custom Multi-Agent Panel Development

For studies spanning anticoagulants and antiplatelet agents with mixed permutation signatures in one validated method.

Permutation-aware incubation conditions
Esterase-stabilized clopidogrel handling
Inhibitor-compensated ticagrelor DDI controls

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Antithrombotic Agent?

If your agent has a specific (CYP × transporter × esterase × prodrug) signature not covered by a pre-built method, Creative Proteomics designs custom workflows around the complete permutation before method development.

Creative Proteomics defines the compound’s full permutation — CYP isoforms, P-gp/BCRP status, esterase sensitivity, prodrug activation, DDI risk profile, biological matrix, and panel composition — before building the analytical method.

Target agent

CYP isoform(s)

P-gp / BCRP status

Esterase / prodrug

DDI risk profile

Panel requirements